Fly News Breaks for February 25, 2019
Feb 25, 2019 | 16:58 EDT
Cowen analyst Yaron Werber assumed coverage on Epizyme with an Outperform and $18 price target. The analyst noted that Tazemetostat is a de-risked asset with approval expected in 2020, and he anticipates $1B in peak sales, making this an "attractive overlooked opportunity."
News For EPZM From the Last 2 Days
There are no results for your query EPZM